Neuroscience companies criticize FDA for drug-approval delays

11/10/2008 | Wall Street Journal, The

Firms affiliated with the Neurotechnology Industry Organization expressed concern over the FDA's failure to meet some drug-approval deadlines and to schedule discussions with companies. Such delays and the agency's tight focus on product safety can slow down drug development for as long as six months, said Ron Cohen, CEO of Acorda Therapeutics. The firm plans in early 2009 to seek FDA approval for Fampridine-SR, a treatment for multiple sclerosis.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ